LumiraDx Platform for POC Covid-19 Testing
The LumiraDx Platform simplifies, scales down, and integrates techniques used in laboratory analyzers to provide lab-comparable diagnostic tests on a single point-of-care instrument.
Read MorePosted by Melanie Hamilton-Basich | Feb 24, 2021 | Covid 19 |
The LumiraDx Platform simplifies, scales down, and integrates techniques used in laboratory analyzers to provide lab-comparable diagnostic tests on a single point-of-care instrument.
Read MorePosted by Melanie Hamilton-Basich | Feb 24, 2021 | Covid 19 |
The lateral flow immunoassay test can be used to screen or to aid in diagnoses of covid-19 in asymptomatic or symptomatic individuals.
Read MorePosted by Laurie Bonner | Feb 24, 2021 | Covid 19, Point-of-Care |
Luminostics’ Clip Covid Rapid Antigen Test uses smartphone technology to detect SARS-CoV-2 viral antigens from nasal swabs in around 30 minutes.
Read MorePosted by Melanie Hamilton-Basich | Feb 22, 2021 | Covid 19 |
The test uses AnteoTech’s AnteoBind technology to support significantly improved sensitivity, and is the first covid-19 rapid self-test authorized by the FDA.
Read MorePosted by Laurie Bonner | Feb 19, 2021 | Covid 19, Point-of-Care |
The proof-of-concept point-of-care lateral flow tests can detect the presence of SARS-Cov-2 and influenza in less than 15 minutes.
Read More